Clinical Trial Update: A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors [Phase 1]

View source ↗

Summary

This update covers a first-in-human Phase 1 study evaluating 89Zr-cRGDY ultrasmall silica particle tracers for malignant brain tumors. The trial status is Activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Pituitary Adenoma

Drugs mentioned

• 89Zr-cRGDY ultrasmall silica particle tracer (Zr-89-labeled cRGDY ultrasmall silica particle tracer)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Brain Cancer, Pituitary Adenoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING